Clinical Trial Update: Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A [Phase 3]

View source ↗

Summary

Results from a Phase 3 safety study of subcutaneous rituximab in CD20-positive diffuse large B-cell lymphoma or CD20-positive follicular lymphoma Grades 1-3A ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2024-11-21